A5065012141- Multiple Myeloma Research and Treatments
- Transplantation: Methods and Outcomes
- Neurological Complications and Syndromes
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Drug-Induced Adverse Reactions
- Renal Transplantation Outcomes and Treatments
Medical University of South Carolina
2023
University of Iowa Hospitals and Clinics
2022
Daratumumab, a CD38-directed monoclonal antibody indicated for multiple myeloma treatment in adult patients, is associated with high incidence of infusion-related reactions (IRRs). Due to CD38 receptor presence the lungs, many present similarly asthma or allergic rhinitis. Montelukast, leukotriene antagonist, has been hypothesized reduce daratumumab IRRs due its efficacy treating rhinitis and receptors lungs. Recently published data reported can be safely administered via rapid rate protocol...
Diabetes (DM) is a common comorbidity in transplant patients with known effects on gastrointestinal (GI) motility and absorption; however, DM's impact immediate release (IR) tacrolimus to LCP-tacrolimus (LCP) conversion ratios has not been studied. This multivariable analysis of retrospective longitudinal cohort study included kidney recipients converted from IR LCP between 2019 2020. The primary outcome was ratio based DM status. Other outcomes variability, rejection, graft loss, death. Of...